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PURPOSE
To establish that a spectroscopic (multi-energy) CT scanner can
differentiate multiple contrast agents and background tissues. This is
clinically significant because it enables multi-phase contrast studies to
be performed in a single scan. eg. A "triple phase liver" is possible in a
one acquisition. This is a significant improvement from dual energy CT
which is limited to non-contrast and post-contrast images from a single
acquisition.
 
METHOD AND MATERIALS
A spectroscopic photon counting micro-CT scanner was constructed.
This scanner, dubbed MARS-CT, uses CERN's energy selective photon
counting detector Medipix. CT scanners based using this technology
are often referred to as Medipix All Resolution Systems (MARS) since
the scanners produces data with energy, spatial, and temporal
information.
Spectroscopic (energy resolved) images where obtained by adjusting
the energy threshold above which the Medipix detector counts photon
interactions. Non-energy resolved images where obtained by summing
together all energies producing images similar to single energy CT
images.
K-edge Contrast agents included pharmacological preparations of
barium, iodine, gadolinium, and lead were imaged in both phantoms
and mice. Principal Components Analysis (PCA) was applied in the
spectral (energy) domain to differentiated the contrast agents.
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RESULTS
K-edge contrast have measurably different spectral characteristics.
Within mice this allows differentiation of contrast agents. On single
energy CT these contrast agents are all "bright" and can not be
differentiated. The left side of the figure shows a volume rendering of
standard intensity CT of a mouse's chest. The right side of the figure
demonstrates the application of PCA to identify iodine and barium.
Iodine in the vascular system is red and barium in the lungs in blue.
 
 
CONCLUSION
Spectroscopic (multi-energy) CT can differentiate multiple contrast
agents. This allows multi-phase imaging protocols to be performed in a
single acquisation. eg. Pre-, portal venous, and delayed phase contrast
in a single scan. This will reduce patient x-ray dose and increase
patient throughput.
 
CLINICAL RELEVANCE/APPLICATION
Multi-energy (spectroscopic) CT allows many phases of contrast
enhancement to be acquired from a single scan.
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by a grant from the RSNA Research and Education Fund?
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3.
Previously Presented/Published: The RSNA requires that all
abstracts submitted for scientific presentation be original work, not
previously presented at other national or international radiological
society meetings and not previously published. An abstract which
includes an increased number of cases with a new analysis of the data
and additionally demonstrates a significant change in results
is considered new research; therefore, such work is eligible for
consideration.  If an abstract merely reflects an increase in the number
of cases with no significant difference in the results, it will not be
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Has this work been previously presented or published?
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with the highest standards of professional integrity and ethics, the
RSNA requires full disclosure of the discussion of the unlabeled use of
a medical device, product, or pharmaceutical that has not been
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investigational or "Off-label" use of a medical device, product or
pharmaceutical that is classified by the FDA as investigational for the
intended use. If you or any of your co-authors will discuss or describe
investigational or unlabeled products, the presenting author is
responsible for disclosing the information to the audience.
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presentations on the Web for a maximum of one year after the RSNA
annual meeting. RSNA scientific presentations posted on the Web are
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Please provide the name of the department chair for the
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Prof Tim Buckenham
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Institution: RSNA provides department chairs a list of presenters of
accepted presentations associated with physicians from their
institutions.  In order to ensure that this work is appropriately
recognized, please indicate the institution at which the presenter is
affiliated:
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Department Chair: Please indicate the name of the presenter's
department chair or highest ranking supervisor:
Prof Tim Buckenham
13.
Department Chair Email Address: Please provide the email address
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Tim.Buckenham@cdhb.govt.nz
14.
Quantitative Imaging is the extraction of quantifiable features from
medical images which add to the clinical assessment of the severity,
degree of change, or relative status of a disease, injury, or chronic
condition.  Quantitative imaging is the development, standardization,
and optimization of anatomical, functional, and molecular imaging
acquisition protocols, data analyses, display methods, and reporting
structures in order to permit the validation of precisely and accurately
obtained image-derived metrics with physiologically relevant
parameters, including treatment response to novel interventions and
clinical outcomes, and the use of such metrics in clinical research and
patient care.
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extraction of clinically relevant quantifiable features from
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